Causes and Management of Non-cirrhotic Portal Hypertension

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2020 Sep 17

PMID 32940785

Citations 27

Authors

Stefania Gioia

Silvia Nardelli

Lorenzo Ridola

Oliviero Riggio

Affiliations

Soon will be listed here.

Abstract

Purpose Of The Review: Non-cirrhotic portal hypertension (NCPH) includes a heterogeneous group of conditions. The aim of this paper is to make an overview on the denominations, diagnostical features and management of porto-sinusoidal vascular disease (PSVD) and chronic portal vein thrombosis (PVT) being the main causes of NCPH in the Western world.

Recent Findings: The management of NCPH consists in the treatment of associated diseases and of portal hypertension (PH). PH due to PSVD or PVT is managed similarly to PH due to cirrhosis. TIPS placement and liver transplantation are considerable options in patients with refractory variceal bleeding/ascites and with progressive liver failure. Anticoagulation is a cornerstone both in the treatment of thrombosis in PSVD and in the prevention of thrombosis recurrence in patients with portal cavernoma. Physicians should be aware of the existence of PSVD and chronic PVT and actively search them in particular settings. To now, the management of portal hypertension-related complications in NCPH is the same of those of cirrhosis. Large cooperative studies on the natural history of NCPH are necessary to better define its management.

Citing Articles

Sleep Disorders: Pathogenesis and Therapeutic Interventions.

Liu C, He Z, Wu Y, Liu Y, Li Z, Jia Y MedComm (2020). 2025; 6(3):e70130.

PMID: 40066230 PMC: 11892028. DOI: 10.1002/mco2.70130.

Porto Sinusoidal Vascular Disorder: A Case Report.

Abdullahi N, Ahmed M, Yusuf M, Warsame H Int Med Case Rep J. 2025; 18:289-293.

PMID: 40046239 PMC: 11881601. DOI: 10.2147/IMCRJ.S502206.

Porto-Sinusoidal Vascular Disease and Downhill Varices: Separate Clinical Entities?.

Pestana I, Ferreira C, Luis R, Sousa R, Pereira E, Banhudo A GE Port J Gastroenterol. 2025; 32(1):54-60.

PMID: 39906509 PMC: 11790272. DOI: 10.1159/000539092.

Safety and Efficacy of Portal Vein Recanalization with Creation of Intrahepatic Portosystemic Shunt (PVR-TIPS) to Treat Chronic Portal Vein Thrombosis in Non-cirrhotic Patients.

Barbosa F, Aseni P, Vertemati M, Becchetti C, Airoldi A, De Gasperi A Cardiovasc Intervent Radiol. 2025; 48(3):351-361.

PMID: 39789254 DOI: 10.1007/s00270-024-03923-6.

Application of liver biopsy in etiological diagnosis of unexplained portal hypertension: Porto-sinusoidal vascular disease should not be ignored.

Zhang Y, Liu H, Xiong Q, Zhong Y, Liu D, Chen W Medicine (Baltimore). 2024; 103(39):e39819.

PMID: 39331914 PMC: 11441879. DOI: 10.1097/MD.0000000000039819.

References

Gioia S, Nardelli S, Ridola L, dAmati G, Riggio O . Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis?. World J Hepatol. 2019; 11(8):613-618. PMC: 6717715. DOI: 10.4254/wjh.v11.i8.613. View

Krishnan P, Fiel M, Rosenkrantz A, Hajdu C, Schiano T, Oyfe I . Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol. 2012; 198(2):370-6. DOI: 10.2214/AJR.11.6855. View

Guido M, Sarcognato S, Sonzogni A, Luca M, Senzolo M, Fagiuoli S . Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int. 2015; 36(3):454-60. DOI: 10.1111/liv.12936. View

Rangari M, Gupta R, Jain M, Malhotra V, Sarin S . Hepatic dysfunction in patients with extrahepatic portal venous obstruction. Liver Int. 2004; 23(6):434-9. DOI: 10.1111/j.1478-3231.2003.00879.x. View

Lv Y, Li K, He C, Luo B, Zhang B, Liu H . TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis. Aliment Pharmacol Ther. 2019; 49(7):926-939. DOI: 10.1111/apt.15186. View

Loinaz C, Colina F, Musella M, Lopez-Rios F, Gomez R, Jimenez C . Orthotopic liver transplantation in 4 patients with portal hypertension and non-cirrhotic nodular liver. Hepatogastroenterology. 1998; 45(23):1787-94. View

De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B . Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2016; 37(5):694-699. DOI: 10.1111/liv.13285. View

Sarin S, Gupta N, Jha S, Agrawal A, Mishra S, Sharma B . Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology. 2010; 139(4):1238-45. DOI: 10.1053/j.gastro.2010.06.017. View

Lattanzi B, Gioia S, Di Cola S, DAmbrosio D, Nardelli S, Tavano D . Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. Liver Int. 2019; 39(10):1937-1942. DOI: 10.1111/liv.14160. View

10.

Guido M, Alves V, Balabaud C, Bathal P, Bioulac-Sage P, Colombari R . Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology. 2018; 74(2):219-226. DOI: 10.1111/his.13738. View

11.

Minguez B, Garcia-Pagan J, Bosch J, Turnes J, Alonso J, Rovira A . Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology. 2006; 43(4):707-14. DOI: 10.1002/hep.21126. View

12.

De Franchis R . Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63(3):743-52. DOI: 10.1016/j.jhep.2015.05.022. View

13.

Bissonnette J, Garcia-Pagan J, Albillos A, Turon F, Ferreira C, Tellez L . Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology. 2016; 64(1):224-31. DOI: 10.1002/hep.28547. View

14.

Sarin S, Wadhawan M, Gupta R, Shahi H . Evaluation of endoscopic variceal ligation (EVL) versus propanolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal rebleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci. 2005; 50(8):1538-47. DOI: 10.1007/s10620-005-2877-1. View

15.

De Gottardi A, Rautou P, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J . Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019; 4(5):399-411. DOI: 10.1016/S2468-1253(19)30047-0. View

16.

Spaander M, Hoekstra J, Hansen B, van Buuren H, Leebeek F, Janssen H . Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013; 11(3):452-9. DOI: 10.1111/jth.12121. View

17.

Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J . Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2009; 51(1):210-8. DOI: 10.1002/hep.23259. View

18.

Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang S, Senzolo M . Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. JAMA Intern Med. 2015; 175(9):1474-80. DOI: 10.1001/jamainternmed.2015.3184. View

19.

Schouten J, Garcia-Pagan J, Valla D, Janssen H . Idiopathic noncirrhotic portal hypertension. Hepatology. 2011; 54(3):1071-81. DOI: 10.1002/hep.24422. View

20.

Sarin S, Kumar A . Noncirrhotic portal hypertension. Clin Liver Dis. 2006; 10(3):627-51, x. DOI: 10.1016/j.cld.2006.08.021. View

Causes and Management of Non-cirrhotic Portal Hypertension​

Causes and Management of Non-cirrhotic Portal Hypertension